Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Moyamoya Disease Ischemic Cerebral Infarction Ischemic Stroke Ischemic Cerebrovascular Accident Transient Ischemic Attack Males or females aged ≥ 18 and ≤ 60 years. 2. Women of childbearing potential (WOCBP) must have a negative urine HCG pregnancy test at Screening and be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% until the completion of the trial or 60 days after discontinuation of study treatment. Women are considered not childbearing if they are > 1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation). If serum bHCG is the standard of care, then this value can be used to determine eligibility. 3. A clinical diagnosis of moyamoya disease, including unilateral and bilateral disease. 4. Previous clinical diagnosis of stroke or transient ischemic attack or undiagnosed infarction evidenced on screening CT or MRI 5. Patients with moyamoya disease underwent extra cranial-to-intracranial (EC-IC) bypass surgery, including direct or indirect or combined EC-IC bypass surgery 6. Capable of understanding the purpose and risk of the study and has signed, in writing, the ICF. If the subject is not capable of this at the time of enrollment, a legally authorized representative will provide written informed consent in accordance with all regulations. 7. Ability to comply with study follow-up  Female subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months. 2. severely disabled, as defined by a Modified Rankin Scale (mRS) score more than 3. 3. History of intracranial hemorrhage. 4. Postoperative intracranial hemorrhage on CT scan at 4 hours after surgery. 5. Dementia or other progressive neurological disease. 6. Known life expectancy < 6 months (for any reason). 7. Known allergy or hypersensitivity to celery. 8. Received treatment with any other investigational drug within 30 days before baseline, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study. 9. Persons unable or unlikely to return for follow-up visits. 10. Any other reasons that, in the opinion of the investigator, make the subject unsuitable for enrollment